Feb 12, 2021
Mallinckrodt Provides Regulatory Update on StrataGraft®
Jan 29, 2021
Mallinckrodt Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
Nov 16, 2020
Mallinckrodt Announces Real World Data on Hepatorenal Syndrome (HRS) and Acute Kidney Injury (AKI) in Patients with Liver Disease at The Liver Meeting Digital Experience
Nov 16, 2020
Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience
Oct 14, 2020
Mallinckrodt Receives Court Approval of "First Day" Motions to Support Business Operations
Oct 12, 2020
Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring
Aug 10, 2020
Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns
Aug 04, 2020
Mallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline Advancements
Jul 15, 2020
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Jun 17, 2020
Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference
Jun 15, 2020
Mallinckrodt to Proceed with Appeal Despite Appellate Court Decision Denying Temporary Injunction in Ongoing Acthar Gel Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)
Jun 15, 2020
Mallinckrodt to Present Phase 3 StrataGraft® Regenerative Skin Tissue Clinical Trial Results on Severe Burns During the Virtual American Burn Association 52nd Annual Meeting
Jun 09, 2020
Mallinckrodt Completes Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration
May 05, 2020
Mallinckrodt plc Reports Earnings for the First Quarter 2020 and Highlights Pipeline Progress
Apr 30, 2020
Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19
Apr 22, 2020
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of New Drug Application for Terlipressin for Treatment of Hepatorenal Syndrome Type 1 (HRS-1)
Apr 16, 2020
Mallinckrodt to Report Earnings Results for First Quarter 2020
Apr 15, 2020
Mallinckrodt Announces Publication of Data on Acthar® Gel (Repository Corticotropin Injection) from its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study in Rheumatoid Arthritis (RA) in Rheumatology and Therapy
Apr 06, 2020
Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft® Regenerative Skin Tissue to U.S. Food and Drug Administration
Apr 01, 2020
Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications